OncoMatch

OncoMatch/Colorectal Cancer (CRC)/MSH2

Colorectal Cancer (CRC)MSH2 Clinical Trials

38 recruiting trials·Updated daily from ClinicalTrials.gov

MSH2 is one of four mismatch repair proteins assessed by IHC; loss of MSH2 defines deficient MMR (dMMR) and predicts MSI-H status, qualifying patients for checkpoint immunotherapy. dMMR CRC responds dramatically to PD-1 blockade — pembrolizumab is first-line standard for dMMR metastatic CRC. Trials explore neoadjuvant immunotherapy, combination checkpoint approaches, and MSI as a predictive biomarker across treatment lines.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting MSH2 Colorectal Cancer (CRC) trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 2/Phase 3

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Centre Hospitalier Universitaire de Besancon

Phase 3

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

Jun Huang

Phase 2/Phase 3

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Sun Yat-sen University

Phase 3

Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer

Sir Run Run Shaw Hospital

Phase 3

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Sun Yat-sen University

Phase 2/Phase 3

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

Sixth Affiliated Hospital, Sun Yat-sen University

Additional trials

More MSH2 Colorectal Cancer (CRC) trials

See all in search →
Phase 2
NCT06792695A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerPhase 214 US sitesNCT06992258A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal CancerPhase 29 US sitesNCT07079631A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerPhase 1/Phase 24 US sitesNCT06529523Tislelizumab in People With Colorectal CancerPhase 21 US siteNCT06959550Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal CancerPhase 21 US siteNCT05411718A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch SyndromePhase 21 US site
18 international trials (no US sites)
NCT06509126Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal CancerPhase 3NCT06923345Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)Phase 2NCT06698757Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal CancerPhase 2NCT06911684Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.Phase 2NCT05970302XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRCPhase 2NCT04920149Mesalamine for Colorectal Cancer Prevention Program in Lynch SyndromePhase 2NCT06908031SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal CancerPhase 2NCT05229003Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCPhase 2NCT05462236MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal CancerPhase 2NCT06856837- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver MetastasesPhase 2NCT07347951A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal CancerPhase 2NCT05771181Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer PatientsPhase 2NCT06580574Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon CancersPhase 2NCT07068763Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal CancerPhase 2NCT06204094Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal CancerPhase 2NCT06002789Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCCPhase 2NCT06722183Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor EntitiesPhase 2NCT05954429A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyPhase 2
Other Colorectal Cancer (CRC) biomarkers

Browse other molecular targets with active Colorectal Cancer (CRC) trials.

KRASNRASBRAFMMR / MSI-HMSH6PMS2MLH1HER2 (ERBB2)EGFR
← All Colorectal Cancer (CRC) clinical trials